Related Experiment Video
Updated: Mar 8, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.6K
Dopamine agonist withdrawal syndrome: A comprehensive review
Xin Xin Yu1, Hubert H Fernandez1
1Center for Neurological Restoration, Cleveland Clinic, 9500 Euclid Ave U2, Cleveland, OH, USA.
Journal of the Neurological Sciences
|January 21, 2017
Summary
Dopamine agonist withdrawal syndrome (DAWS) affects up to 19% of Parkinson disease patients. Recognizing risk factors like impulse control disorders is crucial for preventing this severe complication.
Area of Science:
- Neurology
- Pharmacology
Background:
- Dopamine agonists are standard Parkinson disease (PD) treatments.
- Side effects can necessitate dose reduction or discontinuation.
- Dopamine agonist withdrawal syndrome (DAWS) is a significant complication.
Purpose of the Study:
- To summarize the current understanding of DAWS.
- To identify risk factors for DAWS.
- To emphasize the need for early recognition and monitoring.
Main Methods:
- Literature review of DAWS.
- Analysis of identified risk factors for DAWS.
- Discussion of clinical implications.
Main Results:
- DAWS affects up to 19% of PD patients during dopamine agonist taper.
- Key risk factors include impulse control disorders and higher medication dosage.
- Deep brain stimulation history may also be a risk factor.
Conclusions:
- No standard treatment currently exists for DAWS.
- Early identification of at-risk patients is critical for prevention.
- Close monitoring during dopamine agonist tapering is essential for high-risk individuals.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
995
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
995
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.6K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.6K
01:15Drug Abuse and Addiction: Pharmacological Phenomena
1.4K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.4K
01:29Drugs Affecting Neurotransmitter Synthesis
2.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.4K